LIF:NASDAQLife360, Inc. Analysis
Data as of 2026-06-14 - not real-time
$45.25
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Life360 (LIF) posted a 38% YoY revenue jump to $143.1 M and beat earnings expectations with $0.19 EPS, fueling optimism. The stock trades at $45.25, comfortably above its 20‑day and 50‑day SMAs (≈$43.35) but still below the 200‑day SMA (~$65), while a bullish MACD histogram (+0.20) and a neutral RSI (53.6) suggest limited upside in the immediate term. However, the 30‑day volatility is extremely high at 64.6% and beta ≈2.2, indicating the share is highly sensitive to market swings and has endured a 65% max drawdown, underscoring substantial risk. Valuation metrics are mixed: a forward‑PE of 27.8 is below the industry average (36.8) yet the DCF‑derived fair value of $28.8 is far beneath the current price, implying the market may be overpaying. The company’s strong cash position ($457 M) offsets its $311 M debt, and a newly approved $225 M share‑repurchase program aims to mitigate dilution. Analyst consensus remains bullish with a median price target around $60, reflecting confidence in continued user growth and monetization.
Given the robust top‑line growth, high gross margins (77%) and solid ROE (30%), the fundamentals are compelling, but the negative operating margin (‑5.6%) and elevated risk profile temper enthusiasm. Investors should weigh the upside from subscription and advertising expansion against the volatility, valuation premium, and regulatory scrutiny inherent to location‑tracking services.
Given the robust top‑line growth, high gross margins (77%) and solid ROE (30%), the fundamentals are compelling, but the negative operating margin (‑5.6%) and elevated risk profile temper enthusiasm. Investors should weigh the upside from subscription and advertising expansion against the volatility, valuation premium, and regulatory scrutiny inherent to location‑tracking services.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD but price still below 200‑day SMA
- High short‑term volatility and beta
- Recent earnings beat and share‑repurchase announcement
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained revenue growth (+38% YoY) and expanding user base
- Analyst median price target ~ $60 indicating upside
- Strong cash balance to fund growth and offset debt
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- High gross margins (77%) and improving profitability trajectory
- Strategic diversification into advertising and hardware tracking
- Potential for continued subscription expansion despite regulatory scrutiny
Key Metrics & Analysis
Financial Health
Revenue Growth38.10%
Profit Margin28.21%
P/E Ratio25.9
ROE30.65%
ROA0.71%
Debt/Equity52.07
P/B Ratio6.1
Op. Cash Flow$93.8M
Free Cash Flow$60.4M
Industry P/E36.8
Technical Analysis
TrendNeutral
RSI53.6
Support$37.66
Resistance$49.67
MA 20$43.35
MA 50$43.29
MA 200$65.15
MACDBullish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value$28.82
Target Price$60.79
Upside/Downside34.35%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.22
Volatility64.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.